
India accounts for 6.4% of global zero-dose children in 2024: UN
The new national immunisation coverage data released on Monday by the World Health Organisation (WHO) and UNICEF also highlighted that "India accounted for 49.2% of zero-dose children in South Asia", as per statistics from the Regional Office for South Asia (ROSA).
The term "zero-dose children" refers to those who have not received any routine immunisations, including the first dose of the DTP (diphtheria, tetanus, and pertussis) vaccine. This metric is a critical indicator of access to immunisation services and overall healthcare infrastructure.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Play War Thunder now for free
War Thunder
Play Now
Undo
The report said India accounted for "6.4% of zero-dose children globally". Every year, WHO and UNICEF release global and national routine immunisation coverage estimates (WUENIC).
Gavi, the Vaccine Alliance, analyses what the 2024 WUENIC data says about the state of immunisation in the 57 low- and lower-middle-income countries it supports.
Live Events
Gavi said nearly half (4.9 million) of all the 10.2 million zero-dose children in lower-income countries live in five populous nations - Nigeria, DR Congo, India, Pakistan, and Ethiopia.
It pointed out that coverage with the first dose of the DTP vaccine (DTP1) is an important measure that helps the world understand how many zero-dose children still don't have access to life-saving vaccines.
DTP1 coverage stood at 87 per cent in 2024 - nearly recovered from a four percentage point decrease during the COVID-19 pandemic.
"This means there are half a million fewer zero-dose children in lower-income countries in 2024, thanks mainly to targeted efforts in populous countries like India, DR Congo, and Ethiopia," Gavi said.
The report said in 2024, 89 per cent of infants globally -- about 115 million -- received at least one dose of DTP vaccine, and 85 per cent -- roughly 109 million -- completed all three doses.
Compared to 2023, around 171,000 more children received at least one vaccine, and one million more completed the full three-dose DTP series.
While the gains are modest, they signal continued progress by countries working to protect children, even amid growing challenges, the report said.
Still, nearly 20 million infants missed at least one dose of DTP-containing vaccine last year, including 14.3 million "zero-dose" children who never received a single dose of any vaccine.
That's four million more than the 2024 target needed to stay on track with Immunisation Agenda 2030 goals and 1.4 million more than in 2019, the baseline year for measuring progress, the report said.
"Vaccines save lives, allowing individuals, families, communities, economies, and nations to flourish," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.
"It's encouraging to see a continued increase in the number of children being vaccinated, although we still have a lot of work to do. Drastic cuts in aid, coupled with misinformation about the safety of vaccines, threaten to unwind decades of progress," he said.
The report noted that children often remain un- or under-vaccinated due to a combination of factors, such as limited access to immunisation services, disrupted supply, conflict and instability, or misinformation about vaccines.
Data from 195 countries show that 131 countries have consistently reached at least 90% of children with the first dose of DTP vaccine since 2019, but there has been no significant movement in expanding this group.
Among the countries that reached less than 90% in 2019, only 17 managed to increase their coverage rates in the past five years. Meanwhile, in 47 countries, progress is stalling or worsening. This includes 22 countries that achieved and surpassed the 90% target in 2019 but have since declined.
The data shows conflict and humanitarian crises can quickly erode vaccination progress.
A quarter of the world's infants live in just 26 countries affected by fragility, conflict, or humanitarian crises, yet they make up half of all unvaccinated children globally.
Concerningly, in half of these countries, the number of unvaccinated children has expanded rapidly from 3.6 million in 2019 to 5.4 million in 2024, underscoring the need for humanitarian responses to include immunisation, the report said
Immunisation coverage in the 57 low-income countries supported by Gavi has improved in the past year, reducing the number of un- and under-vaccinated children by roughly 650,000.
At the same time, signs of slippage are emerging in upper-middle- and high-income countries that have previously maintained at least 90% coverage. Even small declines in immunisation coverage can dramatically raise the risk of disease outbreaks and place additional strain on already overstretched health systems.
"The good news is that we have managed to reach more children with life-saving vaccines. But millions of children remain without protection against
preventable diseases
, and that should worry us all," said UNICEF Executive Director Catherine Russell.
"We must act now with determination to overcome barriers like shrinking health budgets, fragile health systems, along with misinformation and access constraints because of conflicts. No child should die from a disease we know how to prevent," she said.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
26 minutes ago
- Time of India
Biocon plans to launch generic Wegovy obesity drug in India by 2027, CEO says
Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years, a top executive told Reuters, seeking to tap into a market that is estimated to grow to $150 billion globally by the early 2030s. The push comes after Danish drugmaker Novo Nordisk and U.S.-based rival Eli Lilly saw skyrocketing demand for their obesity drugs Wegovy and Zepbound. Explore courses from Top Institutes in Select a Course Category MCA Management Operations Management Design Thinking Cybersecurity Data Analytics Degree Data Science Project Management Product Management Leadership Technology Others Healthcare Digital Marketing CXO others PGDM Public Policy Finance Artificial Intelligence Data Science MBA healthcare Skills you'll gain: Programming Proficiency Data Handling & Analysis Cybersecurity Awareness & Skills Artificial Intelligence & Machine Learning Duration: 24 Months Vellore Institute of Technology VIT Master of Computer Applications Starts on Aug 14, 2024 Get Details Biopharmaceutical company Biocon plans to submit a request for approval to India's drug regulator by the end of 2026 and potentially launch in 2027 through a partner, CEO Siddharth Mittal said in an email interview on Tuesday. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giá vàng đang tăng mạnh trong năm 2025 — Các nhà giao dịch thông minh đã tham gia IC Markets Tìm hiểu thêm Undo The company, which also makes insulin products, expects to complete late-stage trials within the next 12 to 18 months, he added. "Biocon is actively progressing with filings for semaglutide in Canada as well as many other emerging markets," Mittal said. Live Events Semaglutide is the active ingredient in Novo's drugs Ozempic and Wegovy, used for diabetes and weight-loss management. Indian generic drugmakers, including Dr Reddy's and Cipla , have been racing to produce cheaper versions of Wegovy when semaglutide goes off patent in 2026. Novo launched Wegovy in India for diabetes and weight-loss management in June after Lilly's Mounjaro sales doubled within a few months following its launch in the south Asian country. Biocon plans to file with Canadian regulatory authorities this quarter for generic versions of Ozempic and later this year for Wegovy versions. "Subject to approval, we could look at a market launch in late 2026 or early 2027," he said. Canada has not approved any such therapies yet, the company said. In addition to Canada, Biocon will focus on large emerging markets such as Brazil and Mexico in Latin America, Malaysia and Hong Kong, countries in the Middle East, as well as Australia, and New Zealand to launch obesity drugs, according to the CEO. In markets where Biocon does not have a direct presence, it is seeking local partnerships to commercialise its products, Mittal said.


Time of India
36 minutes ago
- Time of India
Parkinson's disease: Causes, symptoms, and what to eat or avoid for better management
Source: Wikipedia Parkinson's disease is a progressive neurological disorder that occurs when nerve cells in the brain's basal ganglia become damaged or die, leading to reduced dopamine production. Dopamine is a key chemical that helps regulate smooth and coordinated movement. As levels drop, symptoms like tremors, muscle stiffness, slow movements, and balance problems begin to appear. But Parkinson's affects more than just mobility—it can also impact mood, memory, digestion, and sleep. The condition typically develops around age 60, though early-onset cases can occur, especially in those with a family history. Men are slightly more at risk than women. Affecting nearly 1% of people over 60 worldwide, Parkinson's is the second most common age-related neurodegenerative disease after Alzheimer's. While there's no cure, early diagnosis, lifestyle changes, and proper symptom management can help people maintain independence and improve quality of life. Causes of Parkinson's disease While the exact cause of Parkinson's disease remains unknown, researchers believe it results from a combination of genetic, environmental, and possibly viral factors. The condition is marked by the loss of nerve cells in a part of the brain called the substantia nigra, which leads to a drop in dopamine—a chemical messenger crucial for coordinating movement. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo Low levels of norepinephrine, a related neurotransmitter involved in blood pressure and alertness, have also been linked to the disease. According to a study , Parkinson's is the presence of Lewy bodies, clumps of abnormal proteins (alpha-synuclein) found in the brains of people with the condition. Although their role is not fully understood, these protein deposits may interfere with normal brain function and contribute to the progression of symptoms. In addition to biological changes, certain risk factors increase the likelihood of developing Parkinson's: Sex: Men are about 1.5 times more likely to develop Parkinson's than women. Race: Studies show that white individuals have a higher prevalence compared to Black or Asian populations, possibly due to genetic and environmental influences. Age: Parkinson's most commonly develops between the ages of 50 and 60. Cases under the age of 40 are rare, making up about 4% of total diagnoses. Family history: Having a close relative with Parkinson's increases your risk, suggesting a genetic link in some cases. Toxin exposure: Prolonged exposure to pesticides, herbicides, or other environmental toxins may raise the risk of developing the disease. Head injuries: Traumatic brain injuries have also been associated with a higher risk of Parkinson's later in life. Symptoms of Parkinson 's disease Parkinson's disease often develops slowly, with early signs appearing years before noticeable movement issues. These early symptoms , like reduced sense of smell, constipation, small handwriting, a softer voice, or stooped posture, can be subtle but important to catch early. Main motor symptoms As Parkinson's progresses, four key movement-related symptoms usually emerge: Tremors: Shaking in hands or fingers, especially at rest Bradykinesia: Slower movements and walking Muscle stiffness: Tightness in arms, legs, or trunk Balance issues: Unsteadiness and risk of falls Other signs may include a blank facial expression, reduced blinking, a soft voice, 'freezing' while walking, or shuffling steps. Non-motor symptoms Beyond movement, Parkinson's can affect sleep, mood, memory, and the skin. Common non-motor symptoms include: Sleep problems: Vivid dreams or movement during sleep Depression and anxiety Cognitive issues: Trouble focusing or remembering Skin issues, like seborrheic dermatitis or increased melanoma risk Hallucinations or psychosis: Especially in later stages Because symptoms are varied and can seem unrelated, diagnosis is often delayed. If you notice several of these signs, consult a neurologist for evaluation and early management. Parkinson's disease: What to eat and avoid for better symptom management Source: Wikipedia While Parkinson's disease has no cure, emerging research shows that diet can play a supportive role in managing symptoms and slowing disease progression. According to research , research, nearly 1 million people affected in the U.S., and symptoms like tremors, stiffness, and muscle cramps vary widely. Research suggests, alongside medication, a balanced, nutrient-rich diet may improve treatment effectiveness, reduce side effects, and protect brain health. Certain foods can also support dopamine production, ease constipation, fight fatigue, and reduce inflammation. Though diet isn't a cure, it can significantly enhance quality of life and daily functioning for people living with Parkinson's. Best foods for Parkinson's disease: What to eat to support brain and nerve health Antioxidant-rich foods Antioxidants fight oxidative stress, a key factor in the decline of nerve function in Parkinson's disease. Including colourful fruits and vegetables in your diet can help protect the brain. Berries, leafy greens, tomatoes, nuts, and nightshades like eggplant are rich sources of antioxidants and should be eaten regularly for their neuroprotective benefits. Omega-3 fatty acids Omega-3s are healthy fats known for their anti-inflammatory properties. Found in fatty fish like salmon and sardines, as well as flaxseeds and soybeans, these nutrients may support the health of dopamine-producing neurons. A study published in Frontiers in Aging Neuroscience found that omega-3s could help reduce inflammation and protect brain cells from damage. Nutrient-dense foods People with Parkinson's are more prone to deficiencies in key nutrients like vitamin D, calcium, iron, and vitamin B1 (thiamine). These are important for energy, bone strength, and cognitive health. To prevent deficiencies, include foods like fortified dairy, tofu, whole grains, lentils, spinach, and eggs in your daily meals. Foods to avoid or limit with Parkinson's disease for better symptom control Saturated fats High intake of saturated fats may increase inflammation and is linked to a higher risk of Parkinson's, according to a 2022 review published in Nutrients. Foods like red meat, butter, cheese, palm oil, and fried items should be consumed in moderation, as they may negatively affect brain and heart health. Ultra-processed foods Packaged snacks, sugary drinks (including diet sodas), and canned meals are often low in nutrients and high in additives. Research suggests that ultra-processed foods may impair gut health and accelerate the progression of Parkinson's symptoms. Limiting these items can help maintain better digestive and neurological function. Hard-to-chew or swallow foods As Parkinson's progresses, many people experience difficulty with chewing and swallowing. Avoiding tough, dry, or hard foods becomes essential. Instead, opt for softer textures like stewed vegetables, smoothies, and soups. In later stages, working with a speech or swallowing therapist can help tailor safe and nutritious food choices. By focusing on antioxidant-rich produce, healthy fats, and essential vitamins, while limiting saturated fats and processed foods, individuals with Parkinson's can support their health and manage symptoms more effectively. Always consult a healthcare provider or dietitian before making major dietary changes, especially when managing a neurological condition. Also Read: 5 everyday foods you should never feed your child, according to science


NDTV
43 minutes ago
- NDTV
Covid-19 Summer Wave In The US: 25 States See Significant Increase In Cases, Reports CDC
From Florida to Texas, a total of 25 US states are witnessing a surge in Covid-19 cases. According to the US Centers for Disease Control and Prevention (CDC), as of July 8, 2025, Covid-19 infections are growing or are likely to grow in 25 states, signalling the onset of a "summer wave." The CDC has attributed this resurgence of Covid-19 infections to fading immunity and emergence of new covid variants. According to a Johns Hopkins report, several virological, behavioural, and environmental factors drive summer Covid-19 waves. Additionally, human behaviours like increased use of air-conditioners, frequent social gatherings and travelling during the summer holidays also trigger transmission of the virus. New Covid-19 variants driving 2025 summer wave An uptick in Covid-19 cases in 25 US states has been linked to the rapid circulation of new covid sub-variants - XFG and NB.1.8.1. About NB.1.8.1 and XFG 'Nimbus,' scientifically known as NB.1.8.1, is an Omicron sub-variant. It is known to cause mild to moderate upper-respiratory symptoms. However, the variant gained attention due to its distinctive and extremely painful sore throat symptoms. Most infected individuals have described the severity of the throat pain as "razor blade throat". According CDC, Nimbus accounted for approximately 37% of US cases within two weeks as of June 7. The NB.1.8.1 sub-variant does not cause serious illness. However, it appears to be highly transmissible. XFG 'stratus' covid variant XFG Covid-19 variant (nicknamed Stratus) is spreading rapidly across the globe. The World Health Organisation has designated XFG as a 'Variant Under Monitoring,' which means that the variant or sub-variant needs prioritised attention. Several reports suggest that XFG could become the next dominant variant worldwide. XFG is also a descendant of the Omicron family. Some infected individuals have also reported hoarseness or a rough, raspy voice. Other than these distinct symptoms, both XFG and NB.1.8.1 are likely to cause omicron-like symptoms, including congestion, fatigue, mild cough, fever, loss of taste and smell, runny nose, loss of appetite and muscle aches. Less common symptoms include diarrhea and nausea. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.